启动高效率与平台疗法的预测因素作为多发性硬化症的第一线疾病修饰治疗
Khalid Bin Aziz1,2, Thamer S Alhowaish2,3, Feras Alanazi2,3
1College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Frontiers in neurology
|February 16, 2026
概括
高效疾病修饰疗法 (heDMT) 在沙特阿拉伯越来越多地用于多发性硬化症 (MS) 的第一线治疗. 虽然残疾结果相似,但heDMT改善了治疗的持续性和耐受性.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 临床治疗学 临床治疗学
背景情况:
- 多发性硬化症 (MS) 的管理正在转向早期使用高效疾病修饰疗法 (heDMT).
- 关于中东地区首线heDMT使用的预测因素和结果的现实数据有限.
研究的目的:
- 确定影响第一线头部治疗疗法和复发性复发性多发性硬化症 (RRMS) 的平台疗法之间的选择因素.
- 评估初始治疗类对RRMS患者残疾结果和治疗持续性的影响.
主要方法:
- 沙特阿拉伯826名RRMS患者的回顾性队列研究 (2016-2024年).
- 对于heDMT启动预测器的多变量逻辑回归.
- 对于残疾结果的顺序逻辑回归 (EDSS).
- 对治疗持续和中止的生存分析 (卡普兰-梅尔,考克斯,费恩-格雷).
主要成果:
- 40%的患者开始第一线头部治疗,在晚期治疗期和小脑发病患者中使用量增加.
- 在头部DMT和平台疗法组之间,残疾水平没有显著差异.
- 启动heDMT与更高的治疗持久性和更低的中止风险有关.
结论:
- 在沙特阿拉伯,一线治疗heDMT的使用量有所增加,特别是在小脑发病的患者中.
- 启动热DMT在治疗持久性和耐受性方面提供了显著的好处,尽管残疾结果相似.
- 调查结果支持早期,密集的MS管理,并倡导在该地区更广泛地获得和实施HeDMT.
相关概念视频
Factors Affecting Drug Response: Overview
3.1K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.1K
Psychosis: Goals of Pharmacotherapy
550
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
550
Drug Therapy
315
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
315
Therapeutic Drug Monitoring: Affecting Factors
256
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
256
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
17
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
17


